Revista clinica espanola最新文献

{"title":"Case report: clinical presentation of Monkeypox in pregnancy","authors":"Laura García-Hernández , Ana Hernández-Aceituno , Ricardo Jesus Moreno Saavedra , Eneko Larumbe-Zabala","doi":"10.1016/j.rceng.2024.02.009","DOIUrl":"10.1016/j.rceng.2024.02.009","url":null,"abstract":"","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":"224 4","pages":"Pages 245-247"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139944801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of neutralizing antibodies against SARS-CoV-2 using a rapid serological test in health workers of a Spanish Department of Health in Alicante (Spain) before the booster dose of the vaccine","authors":"A.C. Montagud ,&nbsp;J. Llenas-García ,&nbsp;R. Moragues ,&nbsp;A. Pérez-Bernabeu ,&nbsp;M.J. Alcocer Pertegal ,&nbsp;F.J. García Gómez ,&nbsp;A.M. Gamayo Serna ,&nbsp;H. García Morante ,&nbsp;P. Caballero ,&nbsp;J. Tuells","doi":"10.1016/j.rceng.2024.02.013","DOIUrl":"10.1016/j.rceng.2024.02.013","url":null,"abstract":"<div><h3>Aim</h3><p>To study the prevalence of neutralizing antibodies in healthcare workers and healthcare support personnel after the administration of the second dose of the BNT162b2 vaccine (Pfizer-BioNTech).</p></div><div><h3>Materials and Methods</h3><p>In December 2021, we undertook a study in the Health Department in Orihuela, Alicante (Spain), which consists of 1500 workers. We collected demographic variables about the study participants, and we performed a “point-of-care” immunochromatography test to measure the presence of neutralizing antibodies (OJABIO® SARS-CoV-2 Neutralizing Antibody Detection Kit, manufactured by Wenzhou OJA Biotechnology Co., Ltd. Wenzhou, Zhejiang, China) before the administration of the third dose of the vaccine.</p></div><div><h3>Results</h3><p>We obtained complete information about 964 (64%) workers, which consisted of 290 men and 674 women. The average age was 45,8 years (min. 18, max. 68) and the average time since the last dose of the vaccine was 40,5 weeks (min. 1,71, max. 47,71). A total of 131 participants (13,5%) had suffered infection by SARS-CoV-2 confirmed using RT-PCR. The proportion of participants who showed presence of neutralizing antibodies was 38,5%. In the multivariable analysis, the time since the last dose of the vaccine (aOR week: 1,07; 95%CI: 1,04; 1,09) and previous infection by SARS-CoV-2 (aOR: 3,7; 95CI: 2,39; 5,63) showed a statistically significant association with the presence of neutralizing antibodies.</p></div><div><h3>Conclusions</h3><p>The time since the administration of the last dose of the vaccine and the previous infection by SARS-CoV-2 determined the presence of neutralizing antibodies in 38,5% of the healthcare workers and support workers.</p></div>","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":"224 4","pages":"Pages 197-203"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139998735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cerebral venous thrombosis","authors":"L. Ordieres-Ortega ,&nbsp;S. Moragón-Ledesma ,&nbsp;P. Demelo-Rodríguez","doi":"10.1016/j.rceng.2024.02.015","DOIUrl":"10.1016/j.rceng.2024.02.015","url":null,"abstract":"<div><p>Cerebral venous thrombosis is part of the so-called thrombosis in unusual sites. It is defined as an occlusion in the cerebral venous territory. Its incidence is progressively increasing, especially in developing countries. It is more frequently observed in young women, with hormonal factors such as pregnancy or hormonal contraception being significant risk factors in the development of this condition. The clinical presentation will depend fundamentally on the topography of the thrombosis, with a confirmatory diagnosis based mainly on imaging tests. The treatment generally consists of anticoagulation, and other options may be considered depending on the severity of the case. Overall, the prognosis is better than that of other intracranial vascular disorders. This review describes the current evidence available regarding cerebral venous thrombosis.</p></div>","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":"224 4","pages":"Pages 237-244"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140013890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiological aspects, clinical management and short-term outcomes in elderly patients diagnosed with acute heart failure in the emergency department in Spain: results of the EDEN-34 study","authors":"Ò. Miró ,&nbsp;P. Llorens ,&nbsp;S. Aguiló ,&nbsp;A. Alquézar-Arbé ,&nbsp;C. Fernández ,&nbsp;G. Burillo-Putze ,&nbsp;N.C. Marcos ,&nbsp;A.A. Marañón ,&nbsp;G.S. Oms ,&nbsp;J.G. del Castillo ,&nbsp;SIESTA* (Spanish Investigators in Emergency Situations TeAm)","doi":"10.1016/j.rceng.2024.02.014","DOIUrl":"10.1016/j.rceng.2024.02.014","url":null,"abstract":"<div><h3>Objective</h3><p>To estimate the incidence of acute heart failure (AHF) diagnosis in elderly patients in emergency departments (ED), diagnostic confirmation in hospitalized patients, and short-term adverse events.</p></div><div><h3>Methods</h3><p>All patients aged ≥65 years attended in 52 Spanish EDs during 1 week were included and those diagnosed with AHF were selected. In hospitalized patients, those diagnosed with AHF at discharge were collected. As adverse events, in-hospital and 30-day mortality, and combined adverse event (death or hospitalization) at 30 days post-discharge were collected. Adjusted odds ratios (OR) for association of demographic variables, baseline status and constants at ED arrival with mortality and 30-day post-discharge adverse event were calculated.</p></div><div><h3>Results</h3><p>We included 1,155 patients with AHF (annual incidence: 26.5 per 1000 inhabitants ≥65 years, 95% CI: 25.0–28.1). In 86% the diagnosis of AHF was known at discharge. Overall 30-day mortality was 10.7% and in-hospital mortality was 7.9%, and the combined event in 15.6%. In-hospital and 30-day mortality was associated with arterial hypotension (adjusted OR: 74.0, 95% CI: 5.39–1015. and 42.6, 3.74–485, respectively and hypoxemia (2.14, 1.27–3.61; and 1.87, 1.19–2.93) on arrival at the ED and requiring assistance with ambulation (2.24, 1.04–4.83; and 2.48, 1.27–4.86) and age (per 10-year increment; 1.54, 1.04–2.29; and 1.60, 1.13–2.28). The combined post-discharge adverse event was not associated with any characteristic.</p></div><div><h3>Conclusions</h3><p>AHF is a frequent diagnosis in elderly patients consulting in the ED. The functional impairment, age, hypotension and hypoxemia are the factors most associated with mortality.</p></div>","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":"224 4","pages":"Pages 204-216"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139998732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How to detect non-institutionalized older patients at risk of malnutrition during their hospitalization? Comparison of 8 screening tools for malnutrition or nutritional risk","authors":"I. García-Fuente ,&nbsp;L. Corral-Gudino ,&nbsp;M. Gabella-Martín ,&nbsp;V.E. Olivet-de-la-Fuente ,&nbsp;J. Pérez-Nieto ,&nbsp;P. Miramontes-González","doi":"10.1016/j.rceng.2024.03.003","DOIUrl":"10.1016/j.rceng.2024.03.003","url":null,"abstract":"<div><h3>Background</h3><p>The prevalence of malnutrition is high among the elderly population. Hospital admission is a window of opportunity for its detection.</p></div><div><h3>Objective</h3><p>To assess the concordance of different nutritional scales in hospitalized patients.</p></div><div><h3>Methods</h3><p>Prospective study in non-institutionalized patients over 65 years of age admitted to an internal medicine department. Five malnutrition screening surveys (MNA, MST, MUST, NRS-2000 and CONUT) and three nutritional risk screening surveys (SCREEN 3, 8 and 14) were compared. As gold standard we use the Global Malnutrition Leadership Initiative for Malnutrition (GLIM) definition of malnutrition.</p></div><div><h3>Results</h3><p>Eighty-five patients (37% female, median age 83 years) were included. Forty-eight percent (95% CI 38–59%) of patients were classified as malnourished according to GLIM criteria. The SCREEN 3 scale was the most sensitive (93%; 95% CI 87–98) and MUST the most specific (91%; CI 85–99). The most effective scale for excluding suspected malnutrition was SCREEN 3 (LR− 0.17; 95% CI 0.05−0.53) and the best for confirming it was MST (LR+ 7.08; 95% CI 3.06–16.39). Concordance between the different scales was low or very low with kappa indices between 0.082 and 0.465.</p></div><div><h3>Conclusions</h3><p>A comprehensive approach is needed to detect malnutrition in hospitalized patients. More sensitive scales are more useful in initial screening. Nutritional risk tools could be effective at this stage. In a second step, malnutrition should be confirmed according to established criteria such as GLIM.</p></div>","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":"224 4","pages":"Pages 217-224"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140137657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic impact of chronic obstructive pulmonary disease and bronchial asthma in patients with heart failure","authors":"E. Barge-Caballero ,&nbsp;J. Sieira-Hermida ,&nbsp;G. Barge-Caballero ,&nbsp;D. Couto-Mallón ,&nbsp;M.J. Paniagua-Martín ,&nbsp;D. Enríquez-Vázquez ,&nbsp;P.J. Marcos-Rodríguez ,&nbsp;J. Rodríguez-Capitán ,&nbsp;J.M. Vázquez-Rodríguez ,&nbsp;M.G. Crespo-Leiro","doi":"10.1016/j.rceng.2024.01.007","DOIUrl":"10.1016/j.rceng.2024.01.007","url":null,"abstract":"<div><h3>Purpose</h3><p>To analyze the impact of chronic obstructive pulmonary disease (COPD) and bronchial asthma on therapeutic management and prognosis of patients with heart failure (HF).</p></div><div><h3>Methods</h3><p>Analysis of the information collected in a clinical registry of patients referred to a specialized HF unit from January-2010 to June-2012. Clinical profile, treatment and prognosis of patients was evaluated, according to the presence of COPD or asthma. Survival analyses were conducted by means of Kaplan-Meier and Cox’s methods. Median follow-up was 1493 days.</p></div><div><h3>Results</h3><p>We studied 2577 patients, of which 251 (9.7%) presented COPD and 96 (3.7%) bronchial asthma. Significant differences among study groups were observed regarding to the prescription of beta-blockers (COPD<!--> <!-->=<!--> <!-->89.6%; asthma<!--> <!-->=<!--> <!-->87.5%; no bronchopathy<!--> <!-->=<!--> <!-->94.1%; p<!--> <!-->=<!--> <!-->0.002) and SGLT2 inhibitors (COPD<!--> <!-->=<!--> <!-->35.1%; asthma<!--> <!-->=<!--> <!-->50%; no bronchopathy<!--> <!-->=<!--> <!-->38.3%; <em>p</em> <!-->=<!--> <!-->0.036). Also, patients with bronchial disease received less frequently a defibrillator (COPD<!--> <!-->=<!--> <!-->20.3%; asthma<!--> <!-->=<!--> <!-->20.8%; no broncopathy<!--> <!-->=<!--> <!-->29%; <em>p</em> <!-->=<!--> <!-->0.004).</p><p>COPD was independently associated with increased risk of all-cause mortality (HR<!--> <!-->=<!--> <!-->1.64; 95% CI 1.33–2.02), all-cause death or HF admission (HR<!--> <!-->=<!--> <!-->1.47; 95% CI 1.22–1.76) and cardiovascular death or heart transplantation (HR<!--> <!-->=<!--> <!-->1.39; 95% CI 1.08–1.79) as compared with patients with no bronchopathy. Bronchial asthma was not significantly associated with increased risk of adverse outcomes.</p></div><div><h3>Conclusions</h3><p>COPD, but not asthma, is an adverse independent prognostic factor in patients with HF.</p></div>","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":"224 3","pages":"Pages 123-132"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139704404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic review of clinical trials on antithrombotic therapy with factor XI inhibitors","authors":"A. Franco-Moreno ,&nbsp;N. Muñoz-Rivas ,&nbsp;J. Torres-Macho ,&nbsp;A. Bustamante-Fermosel ,&nbsp;C.L. Ancos-Aracil ,&nbsp;E. Madroñal-Cerezo","doi":"10.1016/j.rceng.2024.01.006","DOIUrl":"10.1016/j.rceng.2024.01.006","url":null,"abstract":"<div><h3>Introduction and objective</h3><p>Data from phase 2 clinical trials suggest that factor XI inhibitors may exhibit a more favorable efficacy/safety profile compared to current antithrombotic therapies. The aim of this systematic review is to analyze the available evidence derived from these studies.</p></div><div><h3>Methods</h3><p>A literature search in the PubMed, Cochrane Library, Scopus, EMBASE databases, and clinical trial registration platforms Clinical Trials and Cochrane Central Register of Controlled was conducted. In accordance with the PRISMA statement, results were reported.</p></div><div><h3>Results</h3><p>A total of 18 completed or ongoing clinical trials addressing multiple scenarios, including atrial fibrillation, stroke, myocardial infarction, and venous thromboembolism, were identified. Evidence from 8 studies with available results was analyzed. Phase 2 studies with factor XI inhibitors, overall, demonstrated an acceptable efficacy and safety profile. The benefit-risk balance, in terms of reducing venous thromboembolism in patients undergoing total knee arthroplasty, was more favorable. For this scenario, factor XI inhibitors showed a 50% reduction in the overall rate of thrombotic complications and a 60% reduction in the rate of bleeding compared to enoxaparin. Modest results in studies involving patients with atrial fibrillation, stroke, and myocardial infarction were observed.</p></div><div><h3>Conclusions</h3><p>Factor XI inhibitors offer new prospects in antithrombotic treatment and prophylaxis. Ongoing phase 3 studies will help define the most suitable drugs and indications.</p></div>","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":"224 3","pages":"Pages 167-177"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139682297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Semi-quantitative pulmonary congestion score: prevalence and diuretic management implications after heart failure discharge","authors":"F.J. Pastor-Pérez,&nbsp;M. Veas-Porlán,&nbsp;N. Fernández-Villa,&nbsp;I.P. Garrido-Bravo,&nbsp;S. Manzano-Fernández,&nbsp;D.A. Pascual-Figal","doi":"10.1016/j.rceng.2024.02.002","DOIUrl":"10.1016/j.rceng.2024.02.002","url":null,"abstract":"<div><h3>Introduction</h3><p>Persistent congestion after heart failure (HF) discharge is associated with a higher risk of readmissions.</p></div><div><h3>Material and methods</h3><p>eighty-two patients included after HF discharge. The aim of the study was to characterize semiquantitatively the degree of pulmonary congestion and its changes, describing the relationship between these findings and diuretic management.</p></div><div><h3>Results</h3><p>On the first visit, despite the absence of clinical congestion in the majority of patients, half of the had some degree of pulmonary congestion by ultrasound. After global assessment in this initial visit (clinical and ultrasound) the diuretic was lowered in 50 patients (60%), kept the same in 16 (20%) and it was increased in the rest. In the 45 patients without ultrasound congestion, diuretic reduction was attempted in 80%, being this strategy successful in the majority of them.</p></div><div><h3>Conclusions</h3><p>Lung ultrasound, using simple quantification methods, allows its real incorporation into clinical practice, helping us in the decision making process.</p></div>","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":"224 3","pages":"Pages 157-161"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139736986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bibliometric analysis of the official journals of internal medicine societies in Europe","authors":"L. Liesa,&nbsp;J.M. Porcel","doi":"10.1016/j.rceng.2024.02.004","DOIUrl":"10.1016/j.rceng.2024.02.004","url":null,"abstract":"<div><h3>Introduction</h3><p>Bibliometrics evaluates the quality of biomedical journals. The aim of this study has been to compare the main bibliometric indexes of the official journals of scientific societies of Internal Medicine in Europe.</p></div><div><h3>Material and methods</h3><p>Bibliometric information was obtained from the Web of Science (WoS) and Scopus databases. Both impact metrics (Journal Impact Factor [JIF], CiteScore) and normalized metrics (Journal Citation Indicator [JCI], Normalized Eigenfactor, Source Normalized Impact per Paper [SNIP] and SCImago Journal Rank [SJR]) of the journals for the year 2022 were analyzed, and their evolution over the last decade was described.</p></div><div><h3>Results</h3><p>Twenty-three official journals from 33 scientific societies were evaluated. Eight journals were included in WoS and 11 in Scopus. The best positioned journals in 2022 were: 1) European Journal of Internal Medicine, which ranked in the first quartile (Q1) for JIF, CiteScore and JCI metrics, exceeding values of 1 in Normalized Eigenfactor and SNIP metrics; 2) Internal and Emergency Medicine, with Q1 for CiteScore and JCI metrics, and with values &gt;1 in Normalized EigenFactor and SNIP metrics; 3) Polish Archives of Internal Medicine, with Q1 for JCI metrics; 4) <span>Revista Clínica Española</span>, with Q2 for JIF, CiteScore and JCI metrics; and 5) Acta Medica Belgica, with Q2 for CiteScore and JCI metrics. These journals increased their impact metrics in the last 3 years, in parallel with the COVID pandemic.</p></div><div><h3>Conclusions</h3><p>Five official journals of European Internal Medicine societies, including <span>Revista Clínica Española</span>, meet high quality standards.</p></div>","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":"224 3","pages":"Pages 133-140"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139748041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sexual dysfunction in women with chronic obstructive lung disease","authors":"N. Alcalá-Rivera ,&nbsp;J. Díez-Manglano","doi":"10.1016/j.rceng.2024.02.007","DOIUrl":"10.1016/j.rceng.2024.02.007","url":null,"abstract":"<div><h3>Objective</h3><p>To determine the prevalence of sexual dysfunction in women with COPD and the factors related to its presence.</p></div><div><h3>Methods</h3><p>Cross-sectional observational study during 2021, including women with COPD diagnosed by spirometry through convenience sampling. Data on age, smoking status, spirometric data, comorbidities and medications used were collected. A sexual health questionnaire was administered.</p></div><div><h3>Results</h3><p>The study included 101 women with a mean age of 59.7 (11.3) years. All had experienced a change in sexual activity, with 44% attributing it to COPD. Among them, 51.5% experienced dyspnea during coitus. The prevalence of sexual dysfunction was 52.5%. Women with sexual dysfunction were older and had a lower Tiffeneau index. Furthermore, they consumed alcohol more frequently and had hypertension and cerebrovascular disease, and less often, they had diabetes and heart failure. However, they scored lower on the Charlson index corrected for age. Patients with sexual dysfunction used inhaled triple therapy less frequently.</p></div><div><h3>Conclusions</h3><p>Sexual dysfunction is common in women with COPD. Further studies are needed to investigate its causes, mechanisms, and potential treatments.</p></div>","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":"224 3","pages":"Pages 150-156"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139901061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}